PT - JOURNAL ARTICLE AU - Green, Rhiannon AU - Marjenberg, Zoe AU - Lip, Gregory Y. H. AU - Banerjee, Amitava AU - Wisnivesky, Juan AU - Delaney, Brendan C. AU - Peluso, Michael J. AU - Wynberg, Elke AU - Abduljawad, Sultan TI - The impact of vaccination on preventing long COVID in the Omicron era: a systematic review and meta-analysis AID - 10.1101/2024.11.19.24317487 DP - 2024 Jan 01 TA - medRxiv PG - 2024.11.19.24317487 4099 - http://medrxiv.org/content/early/2024/11/20/2024.11.19.24317487.short 4100 - http://medrxiv.org/content/early/2024/11/20/2024.11.19.24317487.full AB - Millions worldwide are living with long COVID. Since therapeutic research is ongoing, long COVID prevention is a pragmatic public health strategy. While prior analyses have shown the benefit of primary vaccination, the effect of booster vaccination on preventing long COVID caused by an Omicron infection has not been fully investigated. This systematic review identified 31 observational studies, among which 11 were deemed suitable for pairwise meta-analyses. Herein, the pooled risk of long COVID was 22–29% (P<0.0001 and P<0.0001, respectively) lower for vaccinated (any vaccination) populations versus unvaccinated (10 studies); 19% (P<0.0001) lower for primary course vaccination versus no vaccination (3 studies); 26% (P<0.0001) lower for booster vaccination versus no vaccination (4 studies) and 23% (P=0.0044) lower for booster vaccination versus primary course vaccination (3 studies). These findings indicate that booster vaccination can provide additional protection against long COVID; thereby, highlighting the importance of seasonal vaccination against new SARS-CoV-2 variants.Competing Interest StatementSA is an employee of BioNTech SE. RG and ZM are employees of Maverex Ltd both of whom received consulting fees from BioNTech SE. GYHL: Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi Sankyo, and Anthos. No fees were received personally. He is a National Institute for Health and Care Research (NIHR) Senior Investigator. MJP has received consulting fees from Gilead Sciences, AstraZeneca, BioVie, Apellis Pharmaceuticals, and BioNTech and research support from Aerium Therapeutics and Shionogi, outside the submitted work. AB: Consultant for Perspectum. Speaker for Shionogi and Pfizer. BD: BioNTech; one-off advisory board on long COVID in 2024.Funding StatementThis study was funded by BioNTech SE.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:References for data used for the meta-analyses in this study: 1Congdon, S. et al. Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study. Sci Rep 13, 19688 (2023). https://doi.org/10.1038/s41598-023-46912-4 2Di Fusco, M. et al. Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during Omicron. J Patient Rep Outcomes 7, 77 (2023). https://doi.org/10.1186/s41687-023-00616-5 3Diexer, S. et al. Association between virus variants, vaccination, previous infections, and post-COVID-19 risk. Int J Infect Dis 136, 14-21 (2023). https://doi.org/10.1016/j.ijid.2023.08.019 4Hammel, I. S., Tosi, D. M., Tang, F., Pott, H. & Ruiz, J. G. Frailty as a risk factor for post-acute sequelae of COVID-19 among US veterans during the Delta and Omicron waves. J Am Geriatr Soc 71, 3826-3835 (2023). https://doi.org/10.1111/jgs.18584 5Li, J., Nadua, K., Chong, C. Y. & Yung, C. F. Long COVID prevalence, risk factors and impact of vaccination in the paediatric population: a survey study in Singapore. Ann Acad Med Singap 52, 522-532 (2023). https://doi.org/10.47102/annals-acadmedsg.2023238 6Lundberg-Morris, L. et al. Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study. BMJ 383, e076990 (2023). https://doi.org/10.1136/bmj-2023-076990 7Mazzitelli, M. et al. Risk of hospitalization and sequelae in patients with COVID-19 treated with 3-day early remdesivir vs. controls in the vaccine and Omicron era: A real-life cohort study. J Med Virol 95, e28660 (2023). https://doi.org/10.1002/jmv.28660 8Razzaghi, H. et al. Vaccine effectiveness against long COVID in children. Pediatrics 153 (2024). https://doi.org/10.1542/peds.2023-064446 9Wander, P. L. et al. Rates of ICD-10 Code U09.9 documentation and clinical characteristics of VA patients with post-COVID-19 condition. JAMA Netw Open 6, e2346783 (2023). https://doi.org/10.1001/jamanetworkopen.2023.46783 10Wu, Q. et al. Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescents. medRxiv (2024). 11Antonelli, M. et al. SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study. J Infect 87, 506-515 (2023). https://doi.org/10.1016/j.jinf.2023.08.009 I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.